Robert W. Baird Lowers Inspire Medical Systems (NYSE:INSP) Price Target to $248.00

Inspire Medical Systems (NYSE:INSP) had its target price lowered by analysts at Robert W. Baird from $252.00 to $248.00 in a report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target would indicate a potential upside of 32.50% from the company’s current price.

Other analysts also recently issued reports about the stock. Piper Sandler dropped their target price on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a report on Monday. KeyCorp restated an “overweight” rating and set a $234.00 price objective (down from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Stifel Nicolaus reduced their target price on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research note on Tuesday, January 21st. Wells Fargo & Company lowered their target price on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating for the company in a report on Tuesday. Finally, Morgan Stanley cut their price target on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a report on Tuesday. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $228.82.

Inspire Medical Systems Stock Up 1.7 %

Shares of NYSE INSP opened at $187.17 on Tuesday. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of 174.93 and a beta of 1.32. Inspire Medical Systems has a twelve month low of $123.00 and a twelve month high of $257.40. The company’s fifty day moving average is $189.39 and its 200-day moving average is $191.39.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. On average, research analysts anticipate that Inspire Medical Systems will post 1.33 EPS for the current fiscal year.

Institutional Trading of Inspire Medical Systems

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Inspire Medical Systems by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 3,270,357 shares of the company’s stock worth $606,259,000 after purchasing an additional 38,219 shares during the last quarter. Wasatch Advisors LP grew its stake in shares of Inspire Medical Systems by 1.6% in the third quarter. Wasatch Advisors LP now owns 1,323,470 shares of the company’s stock valued at $279,318,000 after buying an additional 20,481 shares in the last quarter. State Street Corp increased its holdings in Inspire Medical Systems by 78.0% during the third quarter. State Street Corp now owns 1,049,784 shares of the company’s stock worth $221,557,000 after buying an additional 459,990 shares during the last quarter. Janus Henderson Group PLC raised its position in Inspire Medical Systems by 5.8% during the third quarter. Janus Henderson Group PLC now owns 502,609 shares of the company’s stock worth $106,075,000 after acquiring an additional 27,374 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Inspire Medical Systems by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 486,341 shares of the company’s stock valued at $90,188,000 after acquiring an additional 2,687 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.